Rudolf L. Z. Ganzoni

Rudolf L. Z. Ganzoni

Auto-generated profile, based on publicly available information

Rudolf L. Z. Ganzoni

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MKMiroslav Kosar
Miroslav Kosar
DSDavid A. Sykes
David A. Sykes
AVAlexander E. G. Viray
Alexander E. G. Viray
RVRosa Maria Vitale
Rosa Maria Vitale
RSRoman C. Sarott
Roman C. Sarott
ECErick Moran Carreira
Erick Moran Carreira

5 April 2025 in Medicinal Research Reviews
Verified
Journal Article
Closed access
RGRudolf L. Z. Ganzoni
Rudolf L. Z. Ganzoni
SBSofie S. Bournons
Sofie S. Bournons
ECErick Moran Carreira
Erick Moran Carreira
DBDimitri De Bundel
Dimitri De Bundel
ISIlse Smolders
Ilse Smolders

1 April 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
MKMiroslav Kosar
Miroslav Kosar
TPThemiya Perera
Themiya Perera
RGRudolf L. Z. Ganzoni
Rudolf L. Z. Ganzoni
RSRoman C. Sarott
Roman C. Sarott
LBLeire Borrega‐Roman
Leire Borrega‐Roman
DSDavid A. Sykes
David A. Sykes

18 March 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
RGRudolf L. Z. Ganzoni
Rudolf L. Z. Ganzoni
MKMiroslav Kosar
Miroslav Kosar
YHYongqi Han
Yongqi Han
RVRosa Maria Vitale
Rosa Maria Vitale
PAPietro Amodeo
Pietro Amodeo
ECErick Moran Carreira
Erick Moran Carreira
This study, exemplified at CB 2 R, showcases how strategic reutilization of a single ligand scaffold fine-tunes activity of a class A GPCR by virtue of targeting its toggle switch.

1 April 2025 in Angewandte Chemie
Verified
Journal Article
Closed access
MKMiroslav Kosar
Miroslav Kosar
TPThemiya Perera
Themiya Perera
RGRudolf L. Z. Ganzoni
Rudolf L. Z. Ganzoni
RSRoman C. Sarott
Roman C. Sarott
LBLeire Borrega‐Roman
Leire Borrega‐Roman
DSDavid A. Sykes
David A. Sykes

7 May 2026 in bioRxiv
Verified
Preprint
Open access
SBSofie Bournons
Sofie Bournons
MKMiroslav Kosar
Miroslav Kosar
BKBilal Kicin
Bilal Kicin
RSRoman C. Sarott
Roman C. Sarott
EHEvelien Hendrix
Evelien Hendrix
ISIlse Smolders
Ilse Smolders
Temporal lobe epilepsy (TLE) has an unmet need for precision treatments targeting the seizure focus while avoiding effects on other body parts to minimise side effects. Photopharmacology could enable precision treatment by combining systemic administration of a photoswitchable drug with implantation of an optic fibre in the epileptic focus to induce light-dependent drug conversion from an inactive to an active configuration that interacts with its target receptor to suppress seizures. The photoswitchable Δ 9 -tetrahydrocannabinol (Δ 9 -THC) derivative, azo -THC-3, transitions from an inactive trans to an active cis configuration upon UV irradiation. We demonstrate that local or systemic administration of azo -THC-3 and local UV irradiation in the hippocampus supresses difficult-to-treat seizures in the intrahippocampal kainic acid mouse model of TLE. Furthermore, our findings illustrate that the photoswitch strategy avoids hypolocomotion, a common side effect of systemic Δ 9 -THC administration. As such, we provide the first demonstration of seizure suppression with the systemic administration of a photoswitchable compound and its local photoactivation in the seizure focus. Graphical